Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GSR | P00390 | 7/20 | 0.36 |
| ▸ | TDP2 | O95551 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12958663 | 0.86 | MEN1 (0.55) | KDM4EMEN1USP2MAPTIDO1 | |
| SCHEMBL19415772 | 0.79 | KDM4E (0.43) | KDM4EMEN1USP2MAPTIDO1 | |
| SCHEMBL13965822 | 0.77 | KDM4E (0.39) | KDM4EMEN1USP2MAPTIDO1 | |
| SCHEMBL864708 | 0.72 | KDM4E (0.43) | KDM4EMEN1USP2MAPTIDO1 | |
| SCHEMBL12958559 | 0.71 | MEN1 (0.55) | KDM4EMEN1USP2MAPTIDO1 | |
| SCHEMBL15909979 | 0.71 | KDM4E (0.43) | KDM4EMEN1USP2MAPTIDO1 | |
| SCHEMBL16476446 | 0.70 | KDM4E (0.43) | KDM4EMEN1USP2MAPTIDO1 | |
| SCHEMBL13965816 | 0.70 | KCNH2 (0.37) | KDM4EMEN1USP2MAPTIDO1 | |
| Iodide SCHEMBL17254512 | 0.69 | KDM4E (0.43) | KDM4EMEN1USP2MAPTIDO1 | |
| SCHEMBL13965827 | 0.69 | KDM4E (0.39) | KDM4EMEN1USP2MAPTIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLOUNT KENNETH F (US) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | KDM4E 1942/4885MEN1 4416/4885USP2 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.